MODERNA INC (MRNA) Fundamental Analysis & Valuation

NASDAQ:MRNA • US60770K1079

Current stock price

53.72 USD
-0.96 (-1.76%)
At close:
53.874 USD
+0.15 (+0.29%)
After Hours:

This MRNA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. MRNA Profitability Analysis

1.1 Basic Checks

  • MRNA had negative earnings in the past year.
  • MRNA had a negative operating cash flow in the past year.
  • The reported net income has been mixed in the past 5 years: MRNA reported negative net income in multiple years.
  • In multiple years MRNA reported negative operating cash flow during the last 5 years.
MRNA Yearly Net Income VS EBIT VS OCF VS FCFMRNA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5B 10B

1.2 Ratios

  • The Return On Assets of MRNA (-22.87%) is better than 72.92% of its industry peers.
  • MRNA has a Return On Equity of -32.62%. This is in the better half of the industry: MRNA outperforms 74.27% of its industry peers.
Industry RankSector Rank
ROA -22.87%
ROE -32.62%
ROIC N/A
ROA(3y)-24.55%
ROA(5y)1.63%
ROE(3y)-33.11%
ROE(5y)6.13%
ROIC(3y)N/A
ROIC(5y)N/A
MRNA Yearly ROA, ROE, ROICMRNA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40 -40 60 80

1.3 Margins

  • MRNA has a better Gross Margin (70.32%) than 80.66% of its industry peers.
  • MRNA's Gross Margin has declined in the last couple of years.
  • MRNA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 70.32%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.73%
GM growth 5Y-6.61%
MRNA Yearly Profit, Operating, Gross MarginsMRNA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -200 -400 -600 -800

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. MRNA Health Analysis

2.1 Basic Checks

  • MRNA does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • MRNA has more shares outstanding than it did 1 year ago.
  • MRNA has less shares outstanding than it did 5 years ago.
  • The debt/assets ratio for MRNA is higher compared to a year ago.
MRNA Yearly Shares OutstandingMRNA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M
MRNA Yearly Total Debt VS Total AssetsMRNA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B 15B 20B 25B

2.2 Solvency

  • MRNA has an Altman-Z score of 4.14. This indicates that MRNA is financially healthy and has little risk of bankruptcy at the moment.
  • The Altman-Z score of MRNA (4.14) is better than 71.18% of its industry peers.
  • A Debt/Equity ratio of 0.07 indicates that MRNA is not too dependend on debt financing.
  • MRNA has a Debt to Equity ratio of 0.07. This is in the lower half of the industry: MRNA underperforms 60.54% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.07
Debt/FCF N/A
Altman-Z 4.14
ROIC/WACCN/A
WACC9.08%
MRNA Yearly LT Debt VS Equity VS FCFMRNA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5B 10B 15B

2.3 Liquidity

  • MRNA has a Current Ratio of 3.29. This indicates that MRNA is financially healthy and has no problem in meeting its short term obligations.
  • MRNA has a worse Current ratio (3.29) than 60.35% of its industry peers.
  • A Quick Ratio of 3.22 indicates that MRNA has no problem at all paying its short term obligations.
  • MRNA has a Quick ratio of 3.22. This is comparable to the rest of the industry: MRNA outperforms 40.81% of its industry peers.
Industry RankSector Rank
Current Ratio 3.29
Quick Ratio 3.22
MRNA Yearly Current Assets VS Current LiabilitesMRNA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B 15B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. MRNA Growth Analysis

3.1 Past

  • MRNA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 21.66%, which is quite impressive.
  • Looking at the last year, MRNA shows a very negative growth in Revenue. The Revenue has decreased by -39.93% in the last year.
  • The Revenue has been growing by 19.34% on average over the past years. This is quite good.
EPS 1Y (TTM)21.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%27.49%
Revenue 1Y (TTM)-39.93%
Revenue growth 3Y-53.44%
Revenue growth 5Y19.34%
Sales Q2Q%-29.81%

3.2 Future

  • Based on estimates for the next years, MRNA will show a very strong growth in Earnings Per Share. The EPS will grow by 20.56% on average per year.
  • The Revenue is expected to grow by 29.27% on average over the next years. This is a very strong growth
EPS Next Y1.99%
EPS Next 2Y14.34%
EPS Next 3Y15.79%
EPS Next 5Y20.56%
Revenue Next Year10.33%
Revenue Next 2Y12.85%
Revenue Next 3Y15.26%
Revenue Next 5Y29.27%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
MRNA Yearly Revenue VS EstimatesMRNA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 5B 10B 15B
MRNA Yearly EPS VS EstimatesMRNA Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 10 -10 20

More info and screens

Find the best growth stocksShow best growing peers

0

4. MRNA Valuation Analysis

4.1 Price/Earnings Ratio

  • MRNA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year MRNA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MRNA Price Earnings VS Forward Price EarningsMRNA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MRNA Per share dataMRNA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10 15 20

4.3 Compensation for Growth

  • MRNA's earnings are expected to grow with 15.79% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y14.34%
EPS Next 3Y15.79%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. MRNA Dividend Analysis

5.1 Amount

  • MRNA does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

MRNA Fundamentals: All Metrics, Ratios and Statistics

MODERNA INC

NASDAQ:MRNA (4/17/2026, 8:00:02 PM)

After market: 53.874 +0.15 (+0.29%)

53.72

-0.96 (-1.76%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-13
Earnings (Next)05-01
Inst Owners79.19%
Inst Owner Change-0.17%
Ins Owners2.7%
Ins Owner Change1.62%
Market Cap21.30B
Revenue(TTM)1.94B
Net Income(TTM)-2.82B
Analysts56
Price Target45.4 (-15.49%)
Short Float %16.5%
Short Ratio6.89
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)48.99%
Min EPS beat(2)21.72%
Max EPS beat(2)76.27%
EPS beat(4)4
Avg EPS beat(4)37.2%
Min EPS beat(4)21.22%
Max EPS beat(4)76.27%
EPS beat(8)7
Avg EPS beat(8)32.95%
EPS beat(12)10
Avg EPS beat(12)13.09%
EPS beat(16)12
Avg EPS beat(16)11.4%
Revenue beat(2)2
Avg Revenue beat(2)9.26%
Min Revenue beat(2)6.17%
Max Revenue beat(2)12.36%
Revenue beat(4)3
Avg Revenue beat(4)10.37%
Min Revenue beat(4)-0.3%
Max Revenue beat(4)23.26%
Revenue beat(8)7
Avg Revenue beat(8)29.33%
Revenue beat(12)11
Avg Revenue beat(12)27.78%
Revenue beat(16)13
Avg Revenue beat(16)23.1%
PT rev (1m)6.84%
PT rev (3m)20.76%
EPS NQ rev (1m)-23.17%
EPS NQ rev (3m)-12.04%
EPS NY rev (1m)-4.56%
EPS NY rev (3m)0.81%
Revenue NQ rev (1m)5.74%
Revenue NQ rev (3m)-4.79%
Revenue NY rev (1m)0.71%
Revenue NY rev (3m)7.32%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 10.96
P/FCF N/A
P/OCF N/A
P/B 2.46
P/tB 2.49
EV/EBITDA N/A
EPS(TTM)-7.27
EYN/A
EPS(NY)-7.13
Fwd EYN/A
FCF(TTM)-5.23
FCFYN/A
OCF(TTM)-4.72
OCFYN/A
SpS4.9
BVpS21.81
TBVpS21.57
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -22.87%
ROE -32.62%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 70.32%
FCFM N/A
ROA(3y)-24.55%
ROA(5y)1.63%
ROE(3y)-33.11%
ROE(5y)6.13%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.73%
GM growth 5Y-6.61%
F-Score3
Asset Turnover0.16
Health
Industry RankSector Rank
Debt/Equity 0.07
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 93.95%
Cap/Sales 10.39%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.29
Quick Ratio 3.22
Altman-Z 4.14
F-Score3
WACC9.08%
ROIC/WACCN/A
Cap/Depr(3y)254.63%
Cap/Depr(5y)200.25%
Cap/Sales(3y)17.73%
Cap/Sales(5y)11.36%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)21.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%27.49%
EPS Next Y1.99%
EPS Next 2Y14.34%
EPS Next 3Y15.79%
EPS Next 5Y20.56%
Revenue 1Y (TTM)-39.93%
Revenue growth 3Y-53.44%
Revenue growth 5Y19.34%
Sales Q2Q%-29.81%
Revenue Next Year10.33%
Revenue Next 2Y12.85%
Revenue Next 3Y15.26%
Revenue Next 5Y29.27%
EBIT growth 1Y20.35%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year21.48%
EBIT Next 3Y19.62%
EBIT Next 5Y20.77%
FCF growth 1Y48.83%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y37.65%
OCF growth 3YN/A
OCF growth 5YN/A

MODERNA INC / MRNA Fundamental Analysis FAQ

What is the fundamental rating for MRNA stock?

ChartMill assigns a fundamental rating of 3 / 10 to MRNA.


What is the valuation status for MRNA stock?

ChartMill assigns a valuation rating of 0 / 10 to MODERNA INC (MRNA). This can be considered as Overvalued.


Can you provide the profitability details for MODERNA INC?

MODERNA INC (MRNA) has a profitability rating of 2 / 10.


What is the earnings growth outlook for MODERNA INC?

The Earnings per Share (EPS) of MODERNA INC (MRNA) is expected to grow by 1.99% in the next year.